Compare Salesforce Inc (CRM) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Salesforce Inc vs Novartis AG — how do they compare? Salesforce Inc trades at $168.85 (market cap $137.23B), while Novartis AG trades at $150.12 (market cap $288.65B). The key difference: Novartis AG is far larger — about 2.1× Salesforce Inc's market cap, and Novartis AG pays the higher dividend (3.15%). Which is the better fit depends on your goals.
| CRM | NVS | |
|---|---|---|
Market Cap | $137.23B | $288.65B |
Sector | Technology | Health |
52-Week High | $270.25 | $168.62 |
52-Week Low | $150.12 | $113.50 |
Enterprise Value | $167.28B | $328.67B |
Dividend Yield | 1.05% | 3.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Salesforce (CRM) trades at $171.22, up 4.84% today, showing strong momentum despite recent sector volatility. The stock demonstrates robust fundamentals with consistent earnings beats (Q1 2026 EPS of $3.88 vs. $3.13 expected), impressive 77.64% gross margins, and accelerating revenue growth to $37.9B in 2025. Technical indicators show bullish momentum with the current price near pivot point resistance at $170, while analyst consensus remains strongly positive with a $235.90 price target.
The outlook remains favorable given Salesforce's dominant market position, AI-driven growth initiatives, and improving profitability. Key risks include sector-wide software selloffs, AI competition, and macroeconomic sensitivity. With 76.84% analyst buy ratings and strong institutional support, the stock appears undervalued relative to growth prospects despite near-term volatility concerns.
Novartis (NVS) trades at $153.37, down 0.44% today, with a bullish technical signal from moving averages. The company reported $56.67B revenue in 2025 with strong profitability margins (net income margin 23.92%) and recently expanded its oncology pipeline through acquisitions like Myricx Bio. Earnings have been mixed, with a miss in Q1 2026 but a beat in Q4 2025.
Outlook remains stable with revenue projections near $56.6B for 2026, though debt-to-asset ratio has risen to 30.26%. Risks include pipeline execution and competitive pressures. Analysts show cautious optimism with 68% hold ratings, reflecting balanced growth and valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
